/ Lesley Ogilvie

Cloud-based visualization of data serves science in the global fight against resistant pathogens

08.10.2021: Where science meets digitalization: the Global Antimicrobial Resistance Research and Development Hub, or Global AMR R&D Hub, works with huge amounts of research data from all around the world. In its mission to combat resistance to antimicrobial medication, the Hub needed a way of transparently documenting how research funding is used and make this information available to the public. The solution came in the form of a dynamic dashboard based on Microsoft Azure and Power BI. It will help highlight the scientific fields that need further research funding.

Access the full story here.

Public and philanthropic investments in AMR R&D related to animal health vaccines

30.08.2021: Antimicrobial resistance (AMR) not only poses a global threat to public health but also has severe implications for the health and welfare of animal populations. We are pleased to publish a new report that focuses on the current state of R&D funding for animal health vaccines. The collated data and observations arising provide a knowledge base that will aid decision makers in ensuring that public and philanthropic resources are targeting the most promising approaches and areas of greatest impact.

Special thanks to OIE and Health for Animals for their insights and contributions to this report.

Access the report here.

Study Publication: Estimating global market potential for priority health technologies addressing AMR

20.08.2021: One of the challenges inhibiting a more unified and co-ordinated global action in the field of incentives for AMR product development is a lack of evidence and data to quantify the scale of the required intervention. To help address this challenge, we established an Expert Advisory Group tasked with estimating the global market potential for products that they identified as representing some of the greatest unmet medical need for addressing AMR. We are proud to publish the outcomes of this study, which will help inform policy makers of the scale of this part of the AMR challenge and support current thinking on market intervention.

Download the full report and the accompanying policy briefs here.

New collaboration between ICARS and the Global AMR R&D Hub

Translating evidence into action!

12.07.2021: The Global AMR R&D Hub and ICARS are pleased to announce a new partnership that will further strengthen their efforts to translate evidence into action to mitigate antimicrobial resistance (AMR).

The collaboration will harness the power of the Global AMR R&D Hub’s Dynamic Dashboard to explore the current landscape of Operational and Implementation Research within low- and middle-income countries (LMICs), in an effort to connect AMR interventions with concrete outcomes. In doing so, the partners hope to be able to develop a pathway from knowledge to shape policy, programmes and practice.

Read the joint communication from ICARS and the Global AMR R&D Hub here.

Accelerating Antimicrobial Development & Access

04.03.2021: The Hub is proud to put forward to the G7 & G20, key emerging insights from its forthcoming studies that it was tasked to undertake by its board of members and G20 Leaders. The results of our initial studies reiterate the challenges that remain in the post-market space and propose concrete steps forward in accelerating antimicrobial development and access for building a more secure future ecosystem.